# Vifor Pharma clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Vifor Pharma as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vifor Pharma: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/vifor-pharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 25, 2022 | NCT05514951 | Study of the Prevalence of Iron Deficiency in Elderly Patient in Hospital Environment | Vifor Pharma | Not applicable | Completed | Iron-deficiency | 888 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05514951) |
| February 9, 2017 | NCT03047954 | Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis | Vifor Pharma | Phase 3 | Completed | Atopic Dermatitis | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03047954) |
| November 22, 2011 | NCT01477424 | A Drug-Drug Interaction Study of Warfarin and PA21 | Vifor Pharma | Phase 1 | Completed | Drug Interaction Potentiation | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01477424) |
| November 22, 2011 | NCT01477411 | A Drug-Drug Interaction Study of Digoxin and PA21 | Vifor Pharma | Phase 1 | Completed | Drug Interaction Potentiation | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01477411) |
| November 3, 2011 | NCT01464190 | A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients | Vifor Pharma | Phase 3 | Completed | Chronic Kidney Disease Requiring Chronic Dialysis | 659 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01464190) |
| October 18, 2011 | NCT01453608 | A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency | Vifor Pharma | Phase 4 | Completed | Iron Deficiency, Chronic Heart Failure | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01453608) |
| October 17, 2011 | NCT01452906 | A Drug-Drug Interaction Study of Omeprazole and PA21 | Vifor Pharma | Phase 1 | Completed | Healthy | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01452906) |
| September 22, 2011 | NCT01438359 | A Drug-Drug Interaction Study of Furosemide and PA21 | Vifor Pharma | Phase 1 | Completed | Healthy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01438359) |
| July 14, 2011 | NCT01394562 | Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure | Vifor Pharma | Phase 3 | Completed | Iron Deficiency, Chronic Heart Failure | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01394562) |
| March 29, 2011 | NCT01324752 | A Drug-Drug Interaction Study of Losartan and PA21 | Vifor Pharma | Phase 1 | Completed | Drug Interaction Potentiation | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01324752) |
| March 28, 2011 | NCT01324128 | A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients | Vifor Pharma | Phase 3 | Completed | Chronic Kidney Disease Requiring Chronic Dialysis | 1,059 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01324128) |
| May 27, 2010 | NCT01131624 | Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women | Vifor Pharma | Phase 3 | Completed | Anaemia | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01131624) |
| April 26, 2010 | NCT01110356 | Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age | Vifor Pharma | Phase 4 | Completed | Iron Deficiency | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01110356) |
| April 9, 2010 | NCT01101399 | Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy | Vifor Pharma | Phase 3 | Completed | Iron-Deficiency Anemia | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01101399) |
| April 9, 2010 | NCT01100879 | Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy | Vifor Pharma | Phase 4 | Terminated | Iron-Deficiency Anemia | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01100879) |
| October 14, 2009 | NCT00994318 | Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) | Vifor Pharma | Phase 3 | Completed | Iron Deficiency Anaemia, Chronic Kidney Disease | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00994318) |
| April 16, 2009 | NCT00882414 | Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) | Vifor Pharma | Phase 2 | Terminated | Thrombocytosis, Iron-Deficiency Anemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00882414) |
| January 16, 2009 | NCT00824460 | Study of Phosphate Levels in Patients With Chronic Kidney Disease | Vifor Pharma | Phase 2 | Completed | Chronic Kidney Disease | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00824460) |
| January 13, 2009 | NCT00821717 | EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure | Vifor Pharma | Phase 3 | Terminated | Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00821717) |
| December 17, 2008 | NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | Vifor Pharma | Phase 3 | Completed | Inflammatory Bowel Disease, Anemia, Iron Deficiency, Iron-Deficiency Anemia, Crohn's Disease, Ulcerative Colitis | 484 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00810030) |
| December 17, 2008 | NCT00810004 | Maintenance Treatment of Iron Deficiency in IBD Patients | Vifor Pharma | Phase 3 | Completed | Iron Deficiency, Inflammatory Bowel Disease | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00810004) |
| August 27, 2007 | NCT00520780 | Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) | Vifor Pharma | Phase 3 | Completed | Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00520780) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 2 |
| Phase 3 | 11 |
| Phase 4 | 3 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia, Iron-Deficiency | 8 |
| Iron Deficiencies | 8 |
| Anemia | 6 |
| Lymphoproliferative Disorders | 2 |
| Heart Diseases | 2 |
| Inflammatory Bowel Diseases | 2 |
| Renal Insufficiency, Chronic | 2 |
| Dermatitis, Atopic | 1 |
| Crohn Disease | 1 |
| Colitis, Ulcerative | 1 |
| Thrombocytosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Specialized medical facilities in the United States](https://specstream.ai/data/businesses/specialized-medical-facilities/united-states)
- [Fireplace services in the United States](https://specstream.ai/data/businesses/fireplace-services/united-states)
